Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy

Histopathology

Volumn 50, Issue 4, 2007, Pages 409-417

  Pinder, S E ^a,c   Provenzano, E ^a   Earl, H ^a   Ellis, I O ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Breast carcinoma; Histopathology; Neoadjuvant chemotherapy; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST; BREAST BIOPSY; BREAST CARCINOMA; BREAST FIBROSIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CLASSIFICATION; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER TISSUE; CARCINOMA IN SITU; CELL STRUCTURE; CYTOLOGY; DRUG RESPONSE; EXCISION; GOLD STANDARD; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LYMPH NODE; LYMPH NODE METASTASIS; MASTECTOMY; MASTITIS; MICROSCOPY; MITOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REPRODUCIBILITY; REVIEW; SAMPLING; SENTINEL LYMPH NODE BIOPSY; TISSUE FIXATION; TISSUE SECTION; TREATMENT OUTCOME; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; PRACTICE GUIDELINES; PROGNOSIS; RESEARCH DESIGN; SPECIMEN HANDLING;

EID: 33847329670     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02419.x     Document Type: Review

References (23)

1. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 1999; 17; 460-469.
2. Chollet P, Amat S, Cure H et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br. J. Cancer 2002; 86; 1041-1046.
3. Pathology reporting of breast disease. NHSBSP Publication no. 58. Sheffield: NHS Publications 2005.
4. Baslaim MM, Al Malik OA, Al-Sobhi SS et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am. J. Surg. 2002; 184; 299-301.
5. Huang EH, Tucker SL, Strom EA et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2005; 62; 351-357.
6. Pierga JY, Mouret E, Laurence V et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical response. Eur. J. Cancer 2003; 39; 1089-1096.
7. Schneeweiss A, Katretchko J, Sinn HP et al. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs 2004; 15; 127-135.
8. Cure H, Amat S, Penault-Llorca F et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res. Treat. 2002; 76; 37-45.
9. Carder P. Typing breast cancer following primary chemotherapy. Histopathology 1999; 35; 584-585.
10. Newman LA, Pernick NL, Adsay V et al. Histopathologic evidence of tumour regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann. Surg. Oncol. 2003; 10; 734-739.
11. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat. 1992; 22; 207-219.
12. Chollet P, Amat S, Belembaogo E et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br. J. Cancer 2003; 89; 1185-1191.
13. Wang S, Zhang JQ, Qiao XM, Yang DQ, Tong FZ, Liu HJ. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma. Zhonghua Wai Ke Za Zhi 2005; 43; 1011-1013.
14. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am. J. Surg. 2003; 186; 348-350.
15. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005; 446; 489-496.
16. Bottini A, Berruti A, Bersiga A et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res. 1996; 16; 3105-3110.
17. Burcombe RJ, Makris A, Richman PI et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer 2005; 92; 147-155.
18. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM. HER-2/neu expression in locally advanced breast carcinomas. pre- and post-neoadjuvant chemotherapy. Breast Cancer 2005; 12; 294-298.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47; 207-214.
20. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am. J. Clin. Oncol. 1993; 16; 223-228.
21. Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J. Am. Coll. Surg. 1995; 180; 297-306.
22. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimeters or more. J. Natl Cancer Inst. 1990; 3; 1539-1545.
23. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 2002; 20; 1456-1466.